RT info:eu-repo/semantics/article
T1 Universal administration of nirsevimab in infants: an analysis of hospitalisations and paediatric intensive care unit admissions for RSV-associated lower respiratory tract infections
A1 Bermudez Barrezueta, Lorena Concepción
A1 Matías del Pozo, Vanesa
A1 Marugán de Miguelsanz, José Manuel
A1 Infante López, Elena
A1 Uribe Reina, Pilar
A1 Romero del Hombrebueno, Yara
A1 Morales Moreno, Antonio Jesús
A1 Rojo Rello, Silvia
A1 Eiros Bouza, José María
A1 Pino Vázquez, María de la Asunción
K1 Lower respiratory tract infection
K1 Nirsevimab
K1 Paediatric intensive care unit
K1 Respiratory syncytial virus
K1 3201.10 Pediatría
AB The aim of this study was to assess the impact of universal nirsevimab administration on hospitalisations and paediatricintensive care unit (PICU) admissions due to lower respiratory tract infection associated with respiratory syncytial virus(RSV-LRTI). An observational study was conducted at a tertiary hospital in Spain to compare the frequency and charac-teristics of children under five years of age hospitalised for RSV-LRTI between October 2023 and March 2024 (nirsevimabperiod), with the data from two prepandemic COVID- 19 seasons (2018–2019 and 2019–2020) and one postpandemic season(2022–2023). A total of 311 patients were included in the study. During the nirsevimab period, a decrease in the number ofchildren hospitalised for RSV-LRTI was observed, particularly for children under six months of age. Compared with the pre-pandemic period, there was an 83.3% decrease in hospitalisations and a 73.3% reduction in PICU admissions in this age group.Similarly, compared with the postpandemic period, there was a 90.8% reduction in hospitalisations and an 87.9% reductionin PICU admissions. Furthermore, the median age was greater (15.6 months; IQR 11.1–27.3) than it was in the prepandemicperiod (4 months; IQR 1.6–8.9) and postpandemic period (3.4 months; IQR 1.5–10.6) (p < 0.001). Moreover, the length ofhospital stay during the nirsevimab period (4 days; IQR 3–6) was shorter than that observed during the prepandemic period(6 days; IQR 4–9) and the postpandemic period (5 days; IQR 3–8) (p = 0.003).Conclusions: Following the introduction of universal immunoprophylaxis with nirsevimab, notable reductions in hospi-talisations and PICU admissions due to RSV-LRTI were observed among young infants. This resulted in a shift in the ageprofile and a shorter length of hospital stay.
PB Springer
YR 2025
FD 2025
LK https://uvadoc.uva.es/handle/10324/75939
UL https://uvadoc.uva.es/handle/10324/75939
LA eng
NO European Journal of Pediatrics, 2025, vol.184, n. 6
NO Producción Científica
DS UVaDOC
RD 15-jun-2025